Canaccord lowered the firm’s price target on Taysha Gene Therapies to $6 from $7 and keeps a Buy rating on the shares. The firm said they continue to think the totality of data from TSHA-120 in GAN should support filing, but the FDA disagrees. The company indicated that it was not able to successfully argue its case to the Agency and, as such, will be discontinuing the program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TSHA:
- 3 Best Stocks to Buy Now, 9/21/2023, According to Top Analysts
- Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)
- Taysha Gene Therapies to discontinue development of TSHA-120 program
- Taysha Gene Therapies participates in a conference call with Goldman Sachs
- Largest borrow rate increases among liquid names